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Abstract
Background: Traditional prognostic factors in epithelial ovarian cancer (EOC) are inadequate in
predicting recurrence and long-term prognosis, but genome-wide cancer research has recently
provided multiple potentially useful biomarkers. The gene codifying for Mammaglobin B (MGB-2)
has been selected from our previous microarray analysis performed on 19 serous papillary
epithelial ovarian cancers and its expression has been further investigated on multiple histological
subtypes, both at mRNA and protein level. Since, to date, there is no information available on the
prognostic significance of MGB-2 expression in cancer, the aim of this study was to determine its
prognostic potential on survival in a large cohort of well-characterized EOC patients.
Methods: MGB-2 expression was evaluated by quantitative real time-PCR in fresh-frozen tissue
biopsies and was validated by immunohistochemistry in matched formalin fixed-paraffin embedded
tissue samples derived from a total of 106 EOC patients and 27 controls. MGB-2 expression was
then associated with the clinicopathologic features of the tumors and was correlated with clinical
outcome.
Results: MGB-2 expression was found significantly elevated in EOC compared to normal ovarian
controls, both at mRNA and protein level. A good correlation was detected between MGB-2
expression data obtained by the two different techniques. MGB-2 expressing tumors were
significantly associated with several clinicopathologic characteristics defining a less aggressive tumor
behavior. Univariate survival analysis revealed a decreased risk for cancer-related death,
recurrence and disease progression in MGB-2-expressing patients (p < 0.05). Moreover,
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multivariate analysis indicated that high expression levels of MGB-2 transcript (HR = 0.25, 95%,
0.08–0.75, p = 0.014) as well as positive immunostaining for the protein (HR = 0.41, 95%CI, 0.17–
0.99, p = 0.048) had an independent prognostic value for disease-free survival.
Conclusion:  This is the first report documenting that MGB-2 expression characterizes less
aggressive forms of EOC and is correlated with a favorable outcome. These findings suggest that
the determination of MGB-2, especially at molecular level, in EOC tissue obtained after primary
surgery can provide additional prognostic information about the risk of recurrence.
Background
Epithelial ovarian cancer (EOC) accounts for the majority
of ovarian malignancies and is estimated to be the third
most common malignancy of the female genital tract and
the first leading cause of death from gynecological cancer
in the US in 2008 [1]. The paucity of disease specific
symptoms and the lack of effective clinical markers con-
tribute to the high mortality rate of EOC. Although pri-
mary surgical cytoreduction and standard care, based on
first-line chemotherapy with carboplatin and paclitaxel,
successfully induce clinical remission in about 70% of the
cases, prognosis remains poor for as many as 50% of the
patients who will experience recurrence and die of second-
ary disease within 5 years after diagnosis. The pathological
stage, the histological grade, the bulk residual tumor and
the tumor histology constitute the most important prog-
nostic factors and aid clinical decision-making in patients
with EOC [2,3]. Nevertheless, their value in predicting
recurrence and long-term prognosis remains inadequate
[4]. Despite the efficacy of adjuvant chemotherapy in
patients with primary ovarian cancer, occurrence of
relapse is one of the major problem in EOC management.
So, it is of the utmost importance to discover new poten-
tial prognostic biomarkers that may allow stratification of
patients into meaningful prognostic categories, with the
ultimate goal of improving treatment strategies following
primary debulking surgery.
Several new genes involved in epithelial ovarian carcino-
genesis have been identified by high-throughput tran-
scription profiling techniques such as high density
oligonucleotide microarrays. By analyzing the genetic fin-
gerprints of 19 ovarian serous-papillary carcinomas
(OSPCs), our research group has recently identified Mam-
maglobin B (secretoglobin, family 2A, member 1 –
SCGB2A1) as the top differentially expressed gene in
OSPCs compared to normal human ovarian surface epi-
thelium (HOSE) cell controls [5]. Mammaglobin B gene
was first isolated by Becker in 1998 [6] and codifies for a
small secreted protein of the uteroglobin superfamily that
includes nine human secretoglobins localized on chro-
mosome 11q12.2 [7]. Normal expression of MGB-2 has
been described in secretory mucosal epithelia of breast
[6], uterus [6,8] and lacrimal glands [9] and it is likely to
be hormonally induced by androgens, as found in human
ocular tissues [9], prostate [10], and pituitary [11]. Apart
from the ovarian adenocarcinomas, abnormal expression
of MGB-2 has been observed in epithelial tumors originat-
ing from breast [12-14], lung [15], digestive organs [16]
and biliary tract [17]. Our previous study demonstrated
the wide expression of MGB-2 at mRNA and protein level
on multiple histological types of EOC, especially in
endometrioid tumors [18]. A following study on type I
endometrial cancers with endometriod histology reported
a significantly inverse correlation between MGB-2 expres-
sion and tumor grade that is the main prognostic factor
for this neoplasm [19].
Since currently available clinical markers are not com-
pletely satisfactory for the prognostic evaluation of
patients with EOC, in the present study we extended our
molecular and immunohistochemical MGB-2 expression
findings previously reported in ovarian cancer [18] and
analyzed MGB-2 in a larger cohort of clinically well char-
acterized EOC patients. The final goal of this study was to
investigate MGB-2 association with clinicopathological
features and to assess MGB-2 prognostic value.
Methods
Patients and tissue samples
This study was performed on 106 consecutive cases of epi-
thelial ovarian cancer diagnosed and treated at the Divi-
sion of Gynecologic Oncology at University of Brescia,
Italy, between September 2003 and July 2006. Study
approval was obtained from the Institutional Review
Board and all patients signed an informed consent accord-
ing to institutional guidelines. No patient received preop-
erative chemotherapy or radiotherapy. All specimens
examined in this study were collected at primary surgery.
Optimal debulking surgery, defined as no macroscopic
residual disease at the end of the procedure, was achieved
in 42 out of 106 (40%) patients, while the remaining
patients had a residual tumor (TR) greater than 0.5 cm in
diameter. The age of patients ranged from 24 to 88 years,
with a median age of 60 years. Histological subtype and
differentiation grade were assigned according to World
Health Organization (WHO) criteria and were further
reviewed by two experienced pathologists. The staging
procedure was performed according to the International
Federation of Gynecology and Obstetrics (FIGO) systemBMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
Page 3 of 12
(page number not for citation purposes)
standards. Clinical and pathological features are shown in
Table 1. For survival analysis, patients were stratified in
"early-stage" tumors (stage IA to IIB, 25 cases) and in
"advanced-stage" tumors (stage IIC to IV, 81 cases). After
surgery, most patients (96 out of 106, 90%) received a
first line platinum-based chemotherapy. Among the
remaining 10 patients, 4 were not eligible for adjuvant
treatment, 2 received a non platinum-based chemother-
apy, 1 refused adjuvant therapy and 3 did not receive
chemotherapy because of their poor medical condition.
Patients were followed up from the date of surgery until
death or September 30, 2008 (median follow-up, 30.5
months, range 1 – 78 months). Clinical data were col-
lected from medical records and were available for all the
patients. At the time of the last follow-up, 45 (43%)
patients were alive without evidence of disease, 12
(11%) patients were alive with disease and 49 (46%)
patients had died of disease (median OS, 49 months,
CI95% = 33 - ∞).
Ovarian specimens
Briefly, 106 ovarian tumor tissues and 27 normal ovarian
samples from women who underwent oophorectomy for
uterine fibromas or prolapse were enrolled in the study.
Median age of the control group was 55 years (range, 48
to 71 years).
Tissues were identified, sharp-dissected and snap-frozen
in liquid nitrogen within 30 minutes from resection. All
tissue fragments were split for histological confirmation.
The samples were embedded in optimal cutting tempera-
ture (O.C.T.) medium, microdissected and the frozen sec-
tions were stained with hematoxylin and eosin (H&E) to
check epithelial component. Pathological examination
confirmed the absence of disease on normal ovarian biop-
sies. Out of the 106 epithelial ovarian cancer samples
studied, 98 contained at least 70% neoplastic epithelial
cells and were retained for further total RNA extraction.
All the 27 normal ovarian controls were eligible for RNA
extraction and were represented by 7 ovarian surface epi-
thelium brushings, 10 ovarian surface epithelium (HOSE)
primary cell lines and 10 surgical biopsies. Ovarian sur-
face epithelium brushings were obtained with a sterile
cytology brush from the normal ovaries of donors. The
brush was first touched to a glass slide and then immedi-
ately immerged in a solution that preserves RNA quality
(RNAlater®, Applied Biosystems, Applera UK, Cheshire,
UK). The slide was later stained following a modified
Papanicolaou protocol to confirm epithelial content.
Establishment of HOSE primary cell lines
A total of 10 HOSE primary cell lines were established
after sterile processing of samples from surgical biopsies.
HOSE were derived from normal ovarian epithelial tissue
of patients undergoing surgery for benign pathologies.
Pathological examination confirmed the absence of any
neoplastic disease. To obtain pure HOSE short term cell
cultures, the normal ovarian tissue was macrodissected
and incubated in 2 ml collagenase and DNAse for 30 min-
utes at 37°C with occasional agitation. Sheets of HOSE
cell fragments were gently scraped with a rubber scraper
directly into complete growth medium M199/MCDB105
(Invitrogen Life Technologies, Carlsbad, CA, USA/Sigma,
St. Louis, Missouri, USA) supplemented with 10% fetal
bovine serum, 200 μg/ml penicillin and 200 μg/ml strep-
tomycin. Primary cell lines were maintained in the same
complete growth medium at 37°C, 5% CO2 in tissue cul-
ture 6-well plates (Corning, NY, USA) and used to gener-
ate monolayers. Total life of in vitro culture was less then
14 days for all samples. Normal cell cultures were col-
lected for RNA extraction at 70–80% confluence without
being subcultured (passage 0). The epithelial purity of
normal ovarian cell lines were evaluated by immunocyto-
chemical staining with antibody against pan-cytokeratin
and epithelial membrane antigen (EMA) as previously
Table 1: Patients characteristics
Clinicopathological features n %
Age (median, range) ys 60 (24–88)
≤ 40 12 12%
> 40 94 88%
Histological type
clear-cell 11 10%
endometrioid 19 18%
undifferentiated 5 5%
mixed 14 13%
mucinous 3 3%
serous-papillary 54 51%
FIGO stage
≤ IIB 25 24%
> IIB 81 76%
Histological grade
G1 7 7%
G2 13 12%
G3 86 81%
Residual tumor (TR), cm
TR = 0 42 40%
TR ≥ 0.5 64 60%
Ascites
yes 62 58%
no 44 42%
Lymph nodal involvement
negative 53 50%
positive 28 26%
missing 25 24%
Preoperatory CA125 level
< Threshold** 11 10%
≥ Threshold** 92 87%
missing 3 3%
**Threshold = 200 U/ml for pre-menopausal patients & 35 U/ml for 
post-menopausal patients.BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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described [20]. All the cell cultures were composed of at
least 99% epithelial cells and were retained for RNA
extraction.
Total RNA extraction and reverse transcription
Total RNA was obtained from 98 cancer samples includ-
ing 76 primary ovarian tissues with different histologies
and 22 omental metastases, and from three types of nor-
mal controls: 10 HOSE primary cell lines, 10 ovarian
biopsies and 7 ovarian brushings. One hundred mg of fro-
zen tissue were sharply dissected from each sample and
homogenized with a rotary homogenizer (QIAGEN,
Valencia, CA, USA) in RNA Lysis Solution (Invitrogen Life
Technologies). Total RNA was prepared from tissues, cells
and brushings using the PureLink Micro-to-Midi Total
RNA Purification System (Invitrogen Life Technologies).
Purity and RNA quantity were evaluated spectrophoto-
metrically. The RNA integrity was tested on Agilent 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA, USA)
and only RNA samples having an OD 260/280 ratio > 1.8
and an Integrity Number > 8.5 were retained for further
amplification. For the generation of first-strand cDNA, 1
μg of total RNA was reverse-transcribed using random
hexamers in a final volume of 20 μl according to the
SuperScriptTM II RT RNaseH-Reverse Transcriptase proto-
col (Invitrogen Life Technologies).
Quantitative-RealTime-PCR
Real-time polymerase chain reaction was performed in
duplicate by using primer set and probe specific for MGB-
2 gene. All the reactions were carried out on the ABI
PRISM 7000 Sequence detection System (Applied Biosys-
tems) using the TaqMan Universal PCR master Mix and
the following Assay on Demand (Applied Biosystems):
Hs00267180_m1 (Mammaglobin B). One μl of the
reverse transcription volume was used for each PCR reac-
tion in a total volume of 25 μl. The thermal cycling condi-
tions were the following: 10 min at 95°C, 40 cycles of
denaturation at 95°C for 15 sec and annealing-extension
at 60°C for 1 min. The comparative threshold cycle (CT)
method was used for the calculation of amplification fold
as specified by the manufacturer. Commercially available
primers and probe for GADPH mRNA were used for nor-
malization (Applied Biosystems). Mammaglobin B
mRNA quantities were analyzed in duplicate and mean
CT levels were used for further analyses. Results were nor-
malized against GADPH and expressed in relation to a cal-
ibrator sample. Results per PCR reaction were expressed as
relative gene expression, using the delta-delta CT method
[21]. The calibrator was chosen among normal controls
and was given a relative expression value of 1.
Immunohistochemistry on formalin-fixed tissues
To evaluate MGB-2 protein expression level, immunohis-
tochemical staining (IHC) was performed on 106 neo-
plastic samples including 84 primary tumors and 22
omental metastases, and on 10 normal ovaries, stored in
the Department of Pathology at the University of Brescia,
Italy. Formalin-fixed, paraffin-embedded tissues were cut
and stained with Hematoxilin and Eosin (H&E) and ana-
lyzed by a Staff Surgical Pathologist. As controls, surface
epithelia obtained from normal ovaries were used. Briefly,
formalin-fixed, paraffin-embedded tissues were cut at 2
μm, mounted on charged slide, and dried. For immuno-
histochemical analysis, slides were deparaffinized and
rehydrated in graded solutions of ethanol and distilled
water. Endogenous peroxidase was blocked by incubation
with peroxidase-blocking solution (DAKO ChemMate,
CA, USA) for 15 minutes, followed by rinsing in tris-buff-
ered saline (TBS). Non-specific staining was blocked by
treatment with normal goat serum (1:50) for 5 minutes.
The immunohistochemical method involved sequential
application of primary antibody to Mammaglobin diluted
1:50 (Mammaglobin Rabbit Monoclonal Antibody (clone
31A5), Zeta Corporation, Sierra Madre, CA, USA) for 45
minutes, a secondary biotinylated anti-rabbit antibody
diluted 1:20 (Menarini, Florence, Italy) for 15 minutes
and streptavidin-biotin complex diluted 1:20 (Reagent
kit, Menarini) for 15 minutes. The immunoprecipitate
was visualized by treatment with 3'3-diaminobenzidine
(Bio-optica, Milan, Italy) for 5 minutes and counter-
stained by hematoxylin (DAKO ChemMate). Immunos-
taining was considered positive for MGB-2 when at least
10% of neoplastic cells were stained. All samples were
scored quantitatively and qualitatively in 20 and 40 high
power fields in every section (Nikon, Eclipse E400).
Evaluation of immunohistochemistry
All immunohistochemically stained slides were examined
on a multiheaded microscope by two pathologists experi-
enced in EOC, who were blinded to patient outcome.
Both staining extent and staining intensity were consid-
ered for evaluation and a four-tiered scoring system was
used: 0 for negative cases, 1+ for weak, 2+ for moderate,
3+ for strong immunoreactivity. Then, the raw data were
dichotomized as follows: the low (1+), the moderate (2+)
and the high (3+) MGB-2 expressing cases were grouped
for statistical analysis and assigned the designation 1,
whereas the completely negative cases were designated
as 0.
Statistical analysis
The association between MGB-2 mRNA expression and
clinicopathologic parameters was investigated with an
ANOVA using the MGB-2 mRNA relative quantification
value on log scale. The association between IHC,
expressed as binary variables code as score = 0 or score ≥
1, and clinical covariates were evaluated by means of a
Fisher's exact test or logistic regression.BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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For survival analysis, three endpoints (cancer relapse, can-
cer progression and death due to cancer) were used to cal-
culate Disease-Free Survival (DFS), Progression-Free
Survival (PFS) and Overall Survival (OS), respectively.
DFS was defined as the time interval between the date of
surgery and the date of identification of disease recurrence
(37 events), PFS was defined as the time interval between
the date of surgery and the date of identification of pro-
gressive disease (disease not treatable with curative intent,
53 events) and OS was defined as the time interval
between the date of surgery and the date of death (49
events). For all three endpoints the last date of follow-up
was used for censored subjects. Survival analyses were all
performed using the Cox proportionals hazard model,
while survival curves were plotted using the Kaplan-Meier
method. To evaluate the effect of MGB-2 mRNA expres-
sion on prognosis (DFS, PFS or OS) we first divided MGB-
2 mRNA relative quantification values in terziles, com-
puted on the whole set of data, then compared the first
two terziles (Low & Medium) to the highest one (High).
The prognostic significance of MGB-2 expression at pro-
tein level was assessed considering immunostaining as a
binary variable, coded as IHC = 0 or IHC ≥ 1.
Median survival was defined as the time-point where the
KM curves crossed the horizontal line at 50% survival
probability. That is at the time where at least 50% of the
patients in the specific group experienced the event of
interest.
For all endpoints, the independent contribution of MGB-
2 on cancer prognosis was evaluated using two
approaches. First we fitted survival models accounting for
all the clinicopathologic variables known to be associated
with prognosis plus MGB-2. This would evaluate the con-
tribution of MGB-2 on survival corrected for all clinical
covariates (irrespective of their significance in our data).
As some clinical variables had a substantial number of
missing data, we performed multiple imputation (m = 10)
using the MICE algorithm [22].
Second, a model selection of survival fit was performed
using bootstrap resampling in conjunction with stepwise
procedure based on Akaike criterion (AIC) [23]. The
rationale of the procedure is based on the fact that auto-
mated selection procedures are likely to identify noisy var-
iables. Bootstrap can help identify truly independently
associated variables [24]. We performed the variable selec-
tion based on a combination of missing data multiple
imputation (MI) and bootstrap resampling, thus allowing
control for both the variability in the imputation as well
as in the automated selection procedure [24]. Multiple
imputation was performed based on the MICE algorithm
with 10 imputation steps, and each imputed dataset was
bootstrapped using 50 replications, for 500 stepwise pro-
cedures overall. Variables that were selected in at least
70% of the replications were included in the final model.
All the analyses were considered significant at p ≤ 0.05. All
the analyses were performed with the statistical software
R, version 2.8.0 [25].
Results
Mammaglobin B gene expression in ovarian cancer tissues 
and in normal ovarian controls
Mammaglobin B gene expression was tested by qRT-PCR
in 98 neoplastic samples represented by 76 primary EOC
specimens with various histologies and 22 serous omental
metastases. MGB-2 expression in tumors was compared
with three sources of normal cells, including 10 HOSE pri-
mary cell lines, 7 ovarian brushings and 10 ovarian biop-
sies. The optimal cutoff point was determined by means
of a Receiver Operating Characteristic (ROC) curve and it
was set at relative quantification, RQ = 2560. According to
the chosen threshold, 24 out of 27 normal controls were
classified as negative (specificity = 88.9%), while 87 out of
98 EOCs were classified as positive (sensitivity = 88.8%).
A highly significant increase in MGB-2 expression was
found in tumors compared to normal controls (Mann-
Whitney test, p < 0.001). Relationships between MGB-2
expression and clinicopathologic parameters are illus-
trated in Table 2. MGB-2 expression was significantly
lower in primary serous tumors (p = 0.036), serous metas-
tasis (p < 0.01) and undifferentiated (p < 0.01) tumor
compared to endometrioid histotype. Mammaglobin-B
expression significantly decreased with advancing stage
(expression in stage ≤ IIB ~5 times higher than in stage >
IIB, p < 0.01), increasing residual disease (TR > 0 cm vs TR
= 0 cm, p = 0.034), ascites production (p = 0.017) and ele-
vated preoperative CA125 serum level (p = 0.026).
Despite well-differentiated tumors showed higher MGB-2
mRNA expression than moderately and poorly differenti-
ated ones, pairwise differences between both G3 and G2
versus G1 cases for MGB-2 relative gene expression values
were not statistically significant (Table 2).
Expression patterns of Mammaglobin B protein in normal 
ovary and in epithelial ovarian cancer by 
immunohistochemistry
The analysis of 10 normal ovaries showed that MGB-2 was
not constitutively expressed in the celomic epithelium or
in the stroma (Figure 1A) or ciliated epithelium lining
inclusion cysts (data not shown). Of the 106 EOC speci-
mens examined in this study, 42 (40%) cases were posi-
tive for MGB-2 immunoreactivity: 39 out of 84 (46%)
primary ovarian cancers, and 3 out of 22 (14%) omental
metastases. A variable expression of MGB-2 was observed
among different tumor histotypes: the protein was unde-
tectable in most of the serous tumors (44 out of 54, 81%)
independently from their primary or metastatic origin, asBMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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well as in mucinous (2 out of 3, 67%) and undifferenti-
ated adenocarcinomas (4 out of 5, 80%). On the contrary,
most of the endometrioid (15 out of 19, 79%), clear-cell
(7 out of 11, 64%) and mixed tumors (8 out of 14, 57%)
stained positively for the protein. In particular, a strong
immunoreactivity was observed in 5 tumors: 3 with pure
(Figure 1B) and 2 with mixed endometrioid histology.
The staining was restricted to epithelial cancer cells and
localized in the cytoplasm with a diffuse and granular pat-
tern, while reactive stromal cells adjacent to ovarian
tumor cells were found negative in all the pathologic sam-
ples analyzed (Figure 1B). Reduced MGB-2 protein
expression was significantly associated with tumor histol-
ogy (p < 0.001), advanced FIGO stage (p < 0.001), subop-
timal debulking (p = 0.004), presence of ascites (p =
0.010), and lymph nodal involvement (p = 0.056) (Table
3). A non-significant trend toward reduced expression of
MGB-2 protein in less differentiated tumors was observed.
Relationship between MGB-2 protein expression and tumor histology
Next, we evaluated the association between MGB-2 coded
as binary (IHC = 0; IHC ≥ 1) and single histotypes by
means of a logistic regression, with p-value correction for
pairwise multiple comparisons. The odds ratio (OR) of
expressing MGB-2 protein was significantly higher in
endometrioid tumors than in primary (OR = 1.76, padjusted
< 0.001) and metastatic serous EOCs (OR = 1.93, padjusted
< 0.001). Moreover, the probability of observing MGB-2
protein expression in serous metastases was lower than in
Table 2: Association between MGB-2 mRNA expression and clinicopathologic variables in 98 patients.
Parameter Fold change 95%CI p-value
Age at diagnosis (y)
> 40 vs ≤ 40 1.60 0.38 – 6.62 0.517
Histological type
clear-cell vs endometrioid 0.47 0.09 – 2.40 0.361
undifferentiated vs endometrioid 0.05 0.01 – 0.44 < 0.010
serous metastases vs endometriod 0.14 0.04 – 0.53 < 0.010
mixed vs endometriod 0.28 0.06 – 1.23 0.090
mucinous vs endometrioid 0.34 0.03 – 4.08 0.387
serous vs endometrioid 0.26 0.07 – 0.91 0.036
FIGO stage
> IIB vs ≤ IIB 0.19 0.07 – 0.51 < 0.010
Histological grade
G2 vs G1 0.47 0.04 – 4.99 0.642$
G3 vs G1 0.22 0.03 – 1.68 0.159$
G2&G3 vs G1 0.32 0.04 – 2.61 0.337$
Residual tumor (TR), cm
TR ≥ 0.5 vs TR = 0 0.38 0.16 – 0.93 0.034
Ascites
yes vs no 0.37 0.16 – 0.83 0.017
Lymph nodal involvement
positive vs negative 0.53 0.19 – 1.49 0.228
Preoperative CA125 serum level
≥ Threshold vs < Threshold** 0.19 0.04 – 0.81 0.026
** Threshold = 200 U/ml for pre-menopausal patients & Threshold = 35 U/ml for post-menopausal patients.
$ corrected for multiple testing.
Representive immunohistochemical staininig for MGB-2 in  normal ovary and ovarian adenocarcinoma Figure 1
Representive immunohistochemical staininig for 
MGB-2 in normal ovary and ovarian adenocarci-
noma. Celomic epithelium and parenchyma of normal ovary 
are negative for MGB-2 (A). Early-staged ovarian adenocarci-
noma with endometrioid histology showing a staining inten-
sity variable from moderate to strong (B).BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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mixed (OR = 0.64, padjusted = 0.039) and clear-cell (OR =
0.60, padjusted = 0.022) primary EOCs. A good correlation
was found between MGB-2 mRNA levels and protein
scores (n = 98, r = 0.54, p < 0.001, Spearman correlation).
Survival analysis
Relationship between MGB-2 expression at mRNA and protein level 
and overall survival in EOC patients
In the univariate analysis for overall survival, high expres-
sion of MGB-2 mRNA and immunohistochemical score
1+ were significantly correlated to longer survival, as well
as the other traditional prognostic factors (Table 4). The
median OS for the low-medium MGB-2 mRNA expressing
group (65 patients, 36 events) was 33 months (95%CI, 26
to ∞), while it was not defined for the high MGB-2 mRNA
expressing group (33 patients, 11 events). The median OS
for the MGB-2 protein expressing group (42 patients, 12
events) was not defined, while it was 38 months (95%CI,
26 to 60) for the negative group (64 patients, 37 events).
The Kaplan Meier survival curve shown in figure 2A con-
Table 3: Association between MGB-2 protein expression and clinicopathological parameters.
MGB-2 protein expression
ns c o r e  =  0 s c o r e  ≥ 1P *
n (%) n (%)
Total 106 64 (60.4) 42 (39.6)
Age at diagnosis (y)
≤ 40 12 6 (50.0) 6 (50.0)
> 40 94 58 (61.7) 36 (38.3)
0.535
Histological type
endometrioid 19 4 (21.1) 15 (78.9)
clear-cell 11 4 (36.4) 7 (63.6)
undifferentiated 5 4 (80.0) 1 (20.0)
serous-pap.met. 22 19 (86.4) 3 (13.6)
mixed 14 6 (42.9) 8 (57.1)
mucinous 3 2 (66.7) 1 (33.3)
serous-papillary 32 25 (78.1) 7 (21.9)
<0.001
FIGO stage
≤ IIB 25 7 (28.0) 18 (72.0)
> IIB 81 57 (70.4) 24 (29.6)
<0.001
Histological grade
G1 7 2 (28.6) 5 (71.4)
G2 13 6 (46.2) 7 (53.8)
G3 86 56 (65.1) 30 (34.9)
0.092
Residual tumor (TR), cm
TR = 0 42 18 (42.9) 24 (57.1)
TR ≥ 0.5 64 46 (71.9) 18 (28.1)
0.004
Ascites
no 44 20 (45.5) 24 (54.5)
yes 62 44 (71.0) 18 (29.0)
0.010
Lymph nodal involvement
negative 53 27 (50.9) 26 (49.1)
positive 28 21 (75.0) 7 (25.0)
missing 25 16 (64.0) 9 (36.0)
0.056
Preoperatory CA125 level
< Threshold** 11 4 (36.4) 7 (63.6)
≥ Threshold** 92 58 (63.0) 34 (37.0)
missing 3 2 (66.7) 1 (33.3)
0.205
*Fisher exact test.
**Threshold = 200 U/ml for pre-menopausal patients & 35 U/ml for post-menopausal patients.BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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firmed that patients with tumors expressing high levels of
MGB-2 had a prolonged overall survival. When MGB-2
was entered into a multivariate model along with FIGO
stage, age, grade, residual tumor, ascites, preoperative
CA125 serum level and lymph nodal involvement, it
didn't show any significant effect (Table 4). Similarly after
automatic model selection only FIGO stage was kept in
the final model (selected in 94% bootstrap samples) and
addition of MGB-2 to the model delivered no significant
improvement (Table 4).
Relationship between MGB-2 expression at mRNA and protein level 
and disease free survival in EOC patients
Univariate analysis for DFS in the subgroup of 75 patients
showed again that high MGB-2 mRNA expression and
score 1+ were favourable prognostic factors, along with all
the other known prognostic factors (Table 4). The median
DFS for the low-medium MGB-2 mRNA expressing group
(44 patients, 32 events) was 20.6 months (95%CI, 17.3 to
30), while it was not defined for the high MGB-2 mRNA
expressing group (25 patients, 4 events). The median DFS
for the MGB-2 protein expressing group (32 patients, 8
events) was not defined, while it was 25.3 months
(95%CI, 17.6 to 30.5) for the negative group (43 patients,
29 events). The Kaplan Meier survival curve for high ver-
sus low-medium expression of MGB-2 mRNA is shown in
figure 2B. There was a significant difference in DFS for
tumors with high versus low-medium expression of MGB-
2 gene. The favorable effect of MGB-2 on time to recur-
rence was also found when MGB-2 was evaluated by
immunohistochemistry. In the full model accounting for
all clinical covariates MGB-2 mRNA expression was still
highly significant, suggesting an independent contribu-
tion on patients relapse-free survival (HR = 0.25, p =
0.014). Consistently MGB-2 positive immunostaining
showed a reduction in the hazard (HR = 0.41, p = 0.048)
(Table 4). Model selection allowed for inclusion of MGB-
2 mRNA expression (selected in 96% of bootstrap sam-
ples) along with FIGO stage (selected in 88% of bootstrap
samples). When considering MGB-2 score instead of RQ
in the same multivariate model, MGB-2 along with FIGO
stage and ascites presence were selected in the final model
Table 4: Univariate and multivariate survival analyses in relation to MGB-2 and clinical parameters.
OS DFS PFS
Variables N HR 95% CI p N HR 95% CI p N HR 95% CI p
Univariate analysis
MGB-2mRNA RQ
high vs medium & low 98 0.45 0.22–0.87 0.016 69 0.15 0.05–0.37 < 0.001 94 0.36 0.17–0.69 0.002
MGB-2 immunostaining
1+ vs 0 106 0.47 0.24–0.87 0.015 75 0.28 0.12–0.58 < 0.001 102 0.43 0.22–0.77 0.004
Age
> 40 vs ≤ 40 106 1.98 0.77–7.23 0.172 75 2.51 0.84–12.27 0.107 102 1.72 0.73–5.28 0.234
FIGO stage
≤ IIB vs >IIB 106 0.06 0.007–0.24 < 0.001 75 0.13 0.03–0.35 < 0.001 102 0.05 0.006–0.20 < 0.001
Residual tumor
TR ≥ 0.5 vs TR = 0 106 4.62 2.31–10.41 < 0.001 75 2.34 1.22–4.69 0.010 102 4.11 2.17–8.54 < 0.001
Presence of ascites
yes vs no 106 2.64 1.44–5.13 0.001 75 2.66 1.37–5.45 0.003 102 2.52 1.42–4.70 0.001
Lymph nodes
positive vs negative 82 2.93 1.42–6.13 0.004 65 2.93 1.44–5.89 0.004 82 2.43 1.27–4.62 0.008
Grade
G2&G3 vsG1 106 2.95 0.79–26.15 0.118 75 3.04 0.81–27.08 0.110 102 3.17 0.86–28.01 0.092
Preoperative CA125 serum level
≥ Threshold vs < Threshold* 103 2.80 0.95–13.62 0.064 74 4.87 1.30–43.35 0.014 99 3.15 1.07–15.30 0.035
Multivariate analysis**
A.
MGB-2mRNA RQ
high vs medium & low 106 0.79 0.38–1.62 0.52 75 0.25 0.08–0.75 0.014 102 0.63 0.30–1.31 0.22
B.
MGB-2 immunostaining
1+ vs 0 106 1.02 0.51–2.04 0.96 75 0.41 0.17–0.995 0.048 102 0.89 0.46–1.73 0.76
Abbreviations: HR, hazard ratio; CI, confidence interval of the estimated HR.
*Threshold = 200 U/ml for pre-menopausal patients & 35 U/ml for post-menopausal patients.
**Multivariate models were adjusted for stage of disease, grade, age, presence of ascites, residual tumor and lymphatic involvement. Multiple 
imputation data.BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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Univariate survival analyses plots Figure 2
Univariate survival analyses plots. Kaplan Meier analyses showing the pattern of Overall Survival (A), Disease-Free Sur-
vival (B) and Progression-Free Survival (C) relative to MGB-2 mRNA expression. Number of events and patients at risk every 
12 months are displayed.BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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(MGB-2, FIGO stage and ascites presence were selected in
81%, 77% and 70% of bootstrap samples, respectively).
Relationship between MGB-2 expression at mRNA and protein level 
and progression free survival in EOC patients
In the subgroup of 53 patients affected by progressive dis-
ease, those with high MGB-2 mRNA expressing tumors or
positive immunostaining experienced a longer progres-
sion-free survival time, as indicated by Cox regression
analysis (Table 4) and represented by the Kaplan Meier
curve (Figure 2C). The median PFS for the low-medium
MGB-2 mRNA expressing group (62 patients, 41 events)
was 32 months (95%CI, 16 to 36) while it was not
defined for the high MGB-2 mRNA expressing group (32
patients, 10 events). The median PFS for the MGB-2 pro-
tein expressing group (41 patients, 13 events) was not
defined, while it was 32 months (95%CI, 16 to 43) for the
negative group (61 patients, 40 events). However, the
pathological stage was the only independent predictor of
cancer progression in the multivariate model (FIGO stage
selected in 97% of the bootstrap samples), and neither
MGB-2 mRNA nor immunostaining were associated to
PFS (Table 4).
Time dependent ROC
Given the possible interest of MGB-2 mRNA expression as
a clinical marker for prognosis, we tried to identify a rea-
sonable cutoff that might account for disease-free survival
time. To do this, we fitted a time-dependent ROC curve
from censored survival data [26] using a predicted time
point at 36 months. Briefly, this method computes ROC
curves based on a time-dependent status indicator (i.e.
relapse in our case) accounting for censored survival
information. The optimal MGB-2 mRNA cutoff was
approximately RQ ≈ 32768, corresponding to 68.1% sen-
sitivity and 75.3% specificity (AUC = 75.3%).
Discussion
Mammaglobin B is a secretoglobin family member,
known to be normally expressed by mammary gland [6],
human endometrium [8] and pituitary [11] and to be
involved in the development of adenocarcinomas origi-
nating from various organs [12-17], including ovary and
endometrium, as recently described by our group [18,19].
Mammaglobin B is considered as a useful candidate
marker for the molecular detection of minimal residual
disease in lymph nodes [12-14,27,28] and for the diagno-
sis of occult tumor cells in effusions from patients with
various malignancies including those harboring gyneco-
logical cancers [29]. Even though MGB-2 function
remains unknown, its wide-spread overexpression in mul-
tiple histological types of EOC compared to normal
celomic epithelium and its presumably secretory nature
suggest that it could be an attractive diagnostic and prog-
nostic biomarker for ovarian malignancy [18]. Previous
studies have shown an association between the expression
of Mammaglobin A (MGB-1), which is highly homolo-
gous to Mammaglobin B, and less aggressive breast cancer
phenotype, providing independent prognostic informa-
tion for cancer patients' survival outcomes [30-32]. Since
traditional prognostic factors are imperfect predictors of
clinical outcome in epithelial ovarian cancer [4], in this
study we have analyzed the potential prognostic impact of
MGB-2 expression on EOC patient survival.
Although histological subgroups were somehow limited
in their sample size, our current study provides evidence
of a significant MGB-2 up-regulation at both mRNA and
protein level in ovarian cancer, specifically in the endome-
trioid subtype. These results differ from our previous
study [18], where, likely due to the small number of sam-
ples available for statistical analysis, significant differ-
ences in MGB-2 expression were not detected amongst the
different histological types of ovarian cancer. Other than
histology, MGB-2 expression was found significantly asso-
ciated with traditional clinicopathological parameters
indicating favorable prognosis, such as early FIGO stage,
optimal debulking success, absence of ascites, absence of
lymph nodal involvement and normal preoperative
CA125 serum level. In this regard, although FIGO stage
includes lymph nodal status and positive cytology, these
parameters have also been analyzed separately in our
study because of their ascertained clinical prognostic rele-
vance [3]. In our previous study on endometrioid
endometrial cancer, a significant inverse relationship
between MGB-2 expression and differentiation grade had
been demonstrated [19]. Unexpectedly, present investiga-
tion shows a non-significant relationship between MGB-2
expression and histological grade, both at mRNA and pro-
tein level. However, this lack of association may be due to
the imbalanced number of patients available for the anal-
yses in the three subgroups (G1, G2, G3).
Finally, we investigated the potential prognostic value of
MGB-2 expression on patient outcome. Since follow-up
data were available for all 106 patients, survival analysis
was performed on the entire group of ovarian cancer
patients. In the univariate analysis, MGB-2 expression was
significantly correlated with reduced risks of cancer-
related death, recurrence and disease progression. As
shown by Kaplan Meier plots, significantly longer overall
survival and disease-free survival were observed in high
MGB-2-expressing patients compared to those with low/
medium MGB-2 expression as well as in patients showing
positive immunostaining when compared to patient har-
boring MGB-2 negative tumors. Similarly, a significant
improvement in time to progression was identified for
MGB-2 expressing patients, both in terms of mRNA and
protein levels. When a multivariate survival model
accounting for the effect of MGB-2 expression in relationBMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
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to all the other established prognostic indicators was
applied, MGB-2 expression, especially at mRNA level,
retained its independent prognostic significance for dis-
ease-free survival along with FIGO stage, whose prognos-
tic role in EOC is well established [2,3]. It is noteworthy
that MGB-2, although showing higher expression in ovar-
ian cancer with endometrioid histology when compared
to other histologic types, maintained its independent
prognostic value for DFS in the multivariate analysis.
In our study two different techniques (i.e., RT-PCR and
IHC) were used to evaluate MGB-2 expression. In this
regard, tumor marker quantification by real-time PCR is
well known to be less error-prone and much more accu-
rate than IHC, since with the latter technique, negative
histological results may not be representative of the entire
tissue status. Unfortunately, however, although MGB-2
determination at mRNA level might be a potentially use-
ful prognostic marker for planning therapy and follow-up,
to date molecular techniques such as real-time PCR, are
not used in routine clinical practice for ovarian pathology.
Limited information is currently available regarding
MGB-2 biological function or factors regulating its expres-
sion in human tumors. In this regard, recent studies have
ruled out a potential "growth factor" activity of its analog
MGB-1 on tumor cells as MGB-1 ectopic expression in
breast tumor cell lines didn't affect their cellular prolifera-
tion rate in vitro [33]. Furthermore, for Uteroglobin (UG),
the founding member of the secretoglobin superfamily
[34], and to date, the only secretoglobin extensively stud-
ied, tissue-specific expression in the uterus and oviduct
has been shown to be regulated by several steroid hor-
mones and to be enhanced by prolactin [34]. Among its
multiple biological properties, UG binds hydrophobic lig-
ands, such as progesterone and prostaglandins, and seems
to play a homeostatic role against oxidative damage,
inflammation, autoimmunity and cancer [34]. Impor-
tantly, regardless to its yet poorly understood function in
cancer, our MGB-2 expression results, although heteroge-
neous among the ovarian cancer tissues tested, clearly
showed that the highest MGB-2 expression correlated
with favorable clinicopathologic features and reduced risk
of relapse. These findings are therefore consistent with the
results reported for the overexpression of its homologous
MGB-1 in breast cancer patients [30,31]. Indeed, in this
patient population, a prolonged DFS and an association
with favorable prognostic clinical variables, including
positive estrogen and progesterone receptors' status has
previously been reported [30-32].
Conclusion
Our findings support MGB-2 as a novel prognostic marker
in EOC. Its expression status is tightly associated with clin-
icopathologic tumor variables affecting prognosis and is
prominent in early-stage and in endometrioid tumors.
Since MGB-2 has shown an independent prognostic value
for future recurrence, its determination in EOC tissue
samples could be clinically useful in the attempt to iden-
tify patients at different risk of relapse before starting
standard chemotherapy and, subsequently, to optimize
follow up and further adjuvant treatment. Further studies
on a larger patients' cohort are warranted to validate the
prognostic impact of MGB-2 expression on survival.
Abbreviations
MGB-2: human Mammaglobin B; EOC: epithelial ovarian
cancer; HOSE: human ovarian surface epithelium; qRT-
PCR: quantitative Reverse Transcription-Polymerase
Chain Reaction; IHC: immunohistochemistry; H&E:
hematoxilin and eosin; OS: overall survival; DFS: disease-
free survival; PFS: progression free survival; HR: hazard
ratio; CI: confidence interval; OR: odds ratio; MI: multiple
imputation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ADS conceived, coordinated, designed the study, inter-
preted the data and revised the manuscript. RAT carried
out the molecular expression study, reviewed medical
records, designed the database, interpreted the data,
drafted and wrote the report. SC performed statistical
analyses, figures and tables, interpreted the data and
helped to draft the manuscript. AR supervised the research
group and critically reviewed the manuscript. EB helped
in collecting data from medical records, carried out RNA
extraction and critically reviewed the manuscript. FEO
and GT conceived the study, designed the clinical data-
base, helped in reviewing medical records, interpreted the
data and critically reviewed the manuscript. CD and MF
performed pathological and immunohistochemical
study. ER coordinated the immunohistochemical study.
PT and LZ helped in collecting follow-up data. CR and EB
participated in collecting flash-frozen tissue samples and
in establishing HOSE primary cell cultures. SP provided
funds and participated in the design of the study. All of
the authors have read and approved the final manuscript.
Acknowledgements
We wish to thank Prof. Piergiovanni Grigolato and Prof. Fabio Facchetti, 
Dr. Brunella Pasinetti and Dr. Diego Rossetti for help in reviewing medical 
records, Ms. Anna Galletti, Ms. Lucia Fontana, Dr. Maria Ravanini and Dr. 
Amerigo Santoro for their excellent technical support. We wish to thank 
all the staff (surgeons and nurses) working in the OR and in the Division of 
Obstetric and Gynecology at the Brescia Hospital for assistance in collect-
ing tissue samples.
Supported by grants from the Nocivelli and the Berlucchi Foundations 
Brescia, Italy, grants from the Istituto Superiore di Sanità (n° 501/A3/17, 
501/A3/3 and 0027557) Rome, Italy, from the Ministero della Salute BMC Cancer 2009, 9:253 http://www.biomedcentral.com/1471-2407/9/253
Page 12 of 12
(page number not for citation purposes)
(Ricerca Finalizzata 2005), Rome, Italy, the Centre for Innovative Diagnos-
tics and Therapeutics (IDET), Brescia, Italy and NIH R01 CA122728-01A2. 
This investigation was also supported by NIH Research Grant CA-16359 
from the National Cancer Institute to AS.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer
statistics, 2008.  CA Cancer J Clin 2008, 58:71-96.
2. Baak JP, Wisse-Brekelmans EC, Langley FA, Talerman A, Delemarre
JF: Morphometric data to FIGO stage and histological type
and grade for prognosis of ovarian tumours.  Journal of Clinical
Pathology 1986, 39:1340-1346.
3. Kosary CL: FIGO stage, histology, histologic grade, age and
race as prognostic factors in determining survival for cancers
of the female gynecological system: an analysis of 1973–87
SEER cases of cancers of the endometrium, cervix, ovary,
vulva, and vagina.  Semin Surg Oncol 1994, 10:31-46.
4. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA: Molec-
ular predictors of response and outcome in ovarian cancer.
Crit Rev Oncol Hematol 2006, 60:19-37.
5. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti
M, Odicino FE, Pecorelli S, Santin AD: Differential gene expres-
sion profiles between tumor biopsies and short-term pri-
mary cultures of ovarian serous carcinomas: identification of
novel molecular biomarkers for early diagnosis and therapy.
Gynecol Oncol 2006, 103:405-416.
6. Becker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA,
Fleming TP: Identification of mammaglobin B, a novel mem-
ber of uteroglobin gene family.  Genomics 1998, 54:70-78.
7. Ni J, Kalff-Suske M, Gentz R, Schageman J, Beato M, Klug J: All
human genes of the uteroglobin family are localized on chro-
mosome 11q12.2 and form a dense cluster.  Ann NY Acad Sci
2000, 923:25-42.
8. Muller-Schottle F, Classen-Linke I, Beier-Hellwig K, Sterzik K, Beier
HM:  Uteroglobin expression and release in the human
endometrium.  Ann NY Acad Sci 2000, 923:332-335.
9. Stoeckelhuber M, Messmer EM, Schmidt C, Xiao F, Schubert C, Klug
J: Immunohistochemical analysis of secretoglobin SCGB 2A1
expression in human ocular glands and tissues.  Histochem Cell
Biol 2006, 126:103-109.
10. Xiao F, Mirwald A, Papaioannou M, Baniahmad A, Klug J: Secre-
toglobin 2A1 is under selective androgen control mediated
by a peculiar binding site for Sp family transcription factors.
Mol Endocrinol 2005, 19:2964-2978.
11. Sjödin A, Guo D, Lund-Johansen M, Krossnes BK, Lilleng P, Henriks-
son R, Hedman H: Secretoglobins in the human pituitary: high
expression of lipophilin B and its down-regulation in pituitary
adenomas.  Acta Neuropathol (Berl) 2005, 109:381-386.
12. Nissan A, Jager D, Roystacher M, Prus D, Peretz T, Eisenberg I, Fre-
und HR, Scanlan M, Ritter G, Old LJ, Mitrani-Rosenbaum S: Multima-
rker RT-PCR assay for the detection of minimal residual
disease in sentinel lymph nodes of breast cancer patients.  Br
J Cancer 2006, 94:681-685.
13. Ouellette RJ, Richard D, Maïcas E: RT-PCR for mammaglobin
genes, MGB1 and MGB2, identifies breast cancer microme-
tastases in sentinel lymph nodes.  Am J Clin Pathol 2004,
121:637-643. Erratum in: Am J Clin Pathol 2004, 122:813
14. Denninghoff V, Allende D, Paesani F, Garcia A, Avagnina A, Perazzo
F, Abalo E, Crimi G, Elsner B: Sentinel Lymph Node Molecular
Pathology in Breast Carcinoma.  Diagn Mol Pathl 2008,
17:214-219.
15. Sjödin A, Guo D, Sørhaug S, Bjermer L, Henriksson R, Hedman H:
Dysregulated secretoglobin expression in human lung can-
cers.  Lung Cancer 2003, 41:49-56.
16. Aihara T, Fujiwara Y, Miyake Y, Okami J, Okada Y, Iwao K, Sugita Y,
Tomita N, Sakon M, Shiozaki H, Monden M: Mammaglobin B gene
as a novel marker for lymph node micrometastasis in
patients with abdominal cancers.  Cancer Lett 2000, 150:79-84.
17. Okami J, Dohno K, Sakon M, Iwao K, Yamada T, Yamamoto H, Fuji-
wara Y, Nagano H, Umeshita K, Matsuura N, Nakamori S, Monden M:
Genetic detection for micrometastasis in lymph node of bil-
iary tract carcinoma.  Clin Cancer Res 2000, 6:2326-2332.
18. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi
A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mamma-
globin B in epithelial ovarian carcinomas.  Gynecol Oncol 2007,
105:578-585.
19. Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli
F, Bandiera E, Pecorelli S, Santin AD: Mammaglobin B expression
in human endometrial cancer.  Int J Gynecol Cancer 2008,
18:1090-1096.
20. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi
S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ,
Shaughnessy J Jr, Pecorelli S: Gene expression profiles in primary
ovarian serous papillary tumors and normal ovarian epithe-
lium: identification of candidate molecular markers for ovar-
ian cancer diagnosis and therapy.  Int J Cancer 2004, 112:14-25.
21. Livak KJ, Schmittgen TD: Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta
C(T)).  Methods 2001, 25:402-408.
22. Van Buuren S, Oudshoorn K: Flexible multivariate imputation
by MICE.  In TNO-rapport PG 99.054 TNO Prevention and Health
Leiden, The Netherlands; 1999. 
23. Austin PC, Tu JV: Bootstrap methods for developing predictive
models.  Am Stat 2004, 58:131-137.
24. Heymans MW, van Buuren S, Knol DL, van Mechelen W, de Vet HC:
Variable selection under multiple imputation using the boot-
strap in a prognostic study.  BMC Med Res Methodol 2007,
13(7):33.
25. R: A language and environment for statistical computing
[http://www.R-project.org]
26. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves
for censored survival data and a diagnostic marker.  Biometrics
2000, 56:337-344.
27. Ooka M, Sakita I, Fujiwara Y, Tamaki Y, Yamamoto H, Aihara T, Miya-
zaki M, Kadota M, Masuda N, Sugita Y, Iwao K, Monden M: Selection
of mRNA markers for detection of lymph node micrometas-
tases in breast cancer patients.  Oncol Rep 2000, 7:561-566.
28. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M: Mam-
maglobin B as a novel marker for detection of breast cancer
micrometastases in axillary lymph nodes by reverse tran-
scription-polymerase chain reaction.  Breast Cancer Res Treat
1999, 58:137-140.
29. Fiegl M, Haun M, Massoner A, Krugmann J, Müller-Holzner E, Hack R,
Hilbe W, Marth C, Duba HC, Gastl G, Grünewald K: Combination
of cytology, fluorescence in situ hybridization for aneuploidy,
and reverse-transcriptase polymerase chain reaction for
human mammaglobin/mammaglobin B expression
improves diagnosis of malignant effusions.  J Clin Oncol 2004,
22:474-483.
30. Núñez-Villar MJ, Martínez-Arribas F, Pollán M, Lucas AR, Sánchez J,
Tejerina A, Schneider J: Elevated mammaglobin (h-MAM)
expression in breast cancer is associated with clinical and
biological features defining a less aggressive tumour pheno-
type.  Breast Cancer Res 2003, 5:R65-70.
31. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA,
Beex LV, Sweep FC: Mammaglobin is associated with low-
grade, steroid receptor-positive breast tumors from post-
menopausal patients, and has independent prognostic value
for relapse-free survival time.  J Clin Oncol 2004, 22:691-698.
32. Guan XF, Hamedani MK, Adeyinka A, Walker C, Kemp A, Murphy
LC, Watson PH, Leygue E: Relationship between mammaglobin
expression and estrogen receptor status in breast tumors.
Endocrine 2003, 21:245-250.
33. Sjödin A, Ljuslinder I, Henriksson R, Hedman H: Mammaglobin and
lipophilin B expression in breast tumors and their lack of
effect on breast cancer cell proliferation.  Anticancer Res 2008,
28:1493-8.
34. Mukherjee AB, Zhang Z, Chilton BS: Uteroglobin: a steroid-
inducible immunomodulatory protein that founded the
Secretoglobin superfamily.  Endocr Rev 2007, 28:707-25.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/253/pre
pub